New weight loss drug enters early human testing
NCT ID NCT07152002
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times
Summary
This early-stage study tests a new drug called LY4064912 in healthy adults and those with overweight or obesity. The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug and its effect on body weight. The study involves 144 participants and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Collaborative Neuroscience Network - CNS
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-••••
Contact
-
ICON Early Phase Services
RECRUITINGSan Antonio, Texas, 78209, United States
Contact Phone: •••-•••-••••
Contact
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
Contact Phone: •••-•••-••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.